Ethotoin
Chemical compound
From Wikipedia, the free encyclopedia
Ethotoin (previously marketed as Peganone) is an anticonvulsant drug used in the treatment of epilepsy.[1] It is a hydantoin, similar to phenytoin. It is not available in the United States.
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a682022 |
| Pregnancy category |
|
| Routes of administration | By mouth (tablets) |
| ATC code | |
| Pharmacokinetic data | |
| Elimination half-life | 3–9 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.001.514 |
| Chemical and physical data | |
| Formula | C11H12N2O2 |
| Molar mass | 204.229 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Mechanism of action
The mechanism of action of ethotoin is similar to that of phenytoin.[citation needed]
Approval history
- 1957 Peganone was granted Food and Drug Administration (FDA) approval to Abbott Laboratories for treatment of grand mal (tonic clonic) and partial complex (psychomotor) seizures.
- 2003 Peganone was acquired from Abbott Laboratories by Ovation Pharmaceuticals (specialty pharmaceutical company who acquire underpromoted branded pharmaceutical products).
- 2018 It was announced by Recordati Rare Diseases Inc. that due to a combination of low product demand and complex manufacturing difficulties, product manufacturing, distribution and sale was being discontinued.
Indications and usage
Ethotoin is indicated for tonic-clonic and partial complex seizures.[2]
Dosing
Side effects
Side effects include ataxia, visual disturbances, rash, and gastrointestinal problems.[citation needed]
Chemistry
Ethotoin is synthesized by the reaction of benzaldehyde oxynitrile (2) with urea or ammonium bicarbonate, which forms an intermediate urea derivative (3) which on acidic conditions cyclizes to 5-phenylhydantoin (4).[5] Alkylation of this product using ethyl iodide leads to the formation of ethotoin (5).
